A phase II trial found non-inferiority on a sleep questionnaire under a specified margin, rather than proof of identical treatments.
One hundred adults were randomized to a particular cannabis-based multi-herbal formulation or lorazepam for four weeks; eighty-two completed the study. At week four, the mean Pittsburgh Sleep Quality Index difference favored the formulation numerically, and its confidence interval met the predefined 2.1-point non-inferiority margin.
There was no placebo arm, follow-up was short and exclusion of non-completers can affect interpretation. Meeting a chosen margin does not prove equivalence on all clinical and safety outcomes. The result applies to that multi-ingredient preparation, not cannabis generally, and does not establish long-term benefit or withdrawal outcomes.
For a comparative-treatment opinion, explain the outcome, direction of the difference and margin before using the term non-inferior. Do not convert the trial into evidence that one substance can be freely substituted for a benzodiazepine. Formulation identity, study duration and the limits of the comparator design remain essential.
Source reviewed: Phase II randomized controlled trial comparing traditional Thai cannabis based medicine with lorazep (PMC13040682). Forensic implications are interpretive analysis of the supplied paper.
Related reading: Valerian Interaction Claims Need Separate Pharmacokinetic and Sedative Evidence.